Avacta logo

AVCT - Avacta Share Price

130.34p -2.7  -2.0%

Last Trade - 3:05pm

Sector
Healthcare
Size
Small Cap
Market Cap £336.0m
Enterprise Value £282.3m
Revenue £3.20m
Position in Universe 680th / 1800
Bullish
Bearish
Unlock AVCT Revenue
Momentum
Relative Strength (%)
1m +17.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1.62 1.81 2.17 2.74 2.76 5.51 3.90 7.80 +27.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Avacta GroupPlc revenues totaled £1.8M. Net loss totaled to £7M.Results are not comparable due to year end change.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AVCT
Graphical History

Revenue

AVCT Revenue Unlock AVCT Revenue

Net Income

AVCT Net Income Unlock AVCT Revenue

Normalised EPS

AVCT Normalised EPS Unlock AVCT Revenue

PE Ratio Range

AVCT PE Ratio Range Unlock AVCT Revenue

Dividend Yield Range

AVCT Dividend Yield Range Unlock AVCT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AVCT EPS Forecasts Unlock AVCT Revenue
Profile Summary

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated April 29, 2003
Public Since September 8, 2003
No. of Shareholders: n/a
No. of Employees: 119
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 252,652,554
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AVCT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AVCT
Upcoming Events for AVCT
Frequently Asked Questions for Avacta
What is the Avacta share price?

As of 3:05pm, shares in Avacta are trading at 130.34p, giving the company a market capitalisation of £336.0m. This share price information is delayed by 15 minutes.

How has the Avacta share price performed this year?

Shares in Avacta are currently trading at 130.34p and the price has moved by 0.591k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Avacta price has moved by 0.666k% over the past year.

What are the analyst and broker recommendations for Avacta?

Of the analysts with advisory recommendations for Avacta, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Avacta is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Avacta next release its financial results?

Avacta is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Avacta dividend yield?

Avacta does not currently pay a dividend.

Does Avacta pay a dividend?

Avacta does not currently pay a dividend.

When does Avacta next pay dividends?

Avacta does not currently pay a dividend.

How do I buy Avacta shares?

To buy shares in Avacta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Avacta?

Shares in Avacta are currently trading at 130.34p, giving the company a market capitalisation of £336.0m.

Where are Avacta shares listed? Where are Avacta shares listed?

Here are the trading details for Avacta:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: AVCT
What kind of share is Avacta?

Based on an overall assessment of its quality, value and momentum, Avacta is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Avacta share price forecast 2021?

Shares in Avacta are currently priced at 130.34p. At that level they are trading at 0.133% discount to the analyst consensus target price of 130.51.

Analysts covering Avacta currently have a consensus Earnings Per Share (EPS) forecast of -0.054 for the next financial year.

How can I tell whether the Avacta share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avacta. Over the past six months, the relative strength of its shares against the market has been -7.73%. At the current price of 130.34p, shares in Avacta are trading at -1.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Avacta PE Ratio?

We were not able to find PE ratio data for Avacta.

Who are the key directors of Avacta?

Avacta's management team is headed by:

Alastair Smith - CEO
Gwyn Humphreys - NED
Trevor Nicholls - NED
Michael Owen - NED
Tony Gardiner - CFO
Eliot Forster - NEC
Jose Saro - OTH
Paul Fry - NED
Neil Bell - OTH
Who are the major shareholders of Avacta?

Here are the top five shareholders of Avacta based on the size of their shareholding:

Premier Asset Management Ltd Investment Advisor/Hedge Fund
Percentage owned: 4.6% (11.6m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 4.56% (11.5m shares)
Lombard Odier Asset Management (Europe) Ltd Investment Advisor
Percentage owned: 3.95% (9.98m shares)
Kamani (Umar Mahmud) Individual Investor
Percentage owned: 3.41% (8.60m shares)
J O Hambro Capital Management Limited Investment Advisor/Hedge Fund
Percentage owned: 3.41% (8.63m shares)
Similar to AVCT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.